Evidence map›Paper›PMID 34497684›Full record

ArticleOxidative medicine and cellular longevity2021

Prognostic Nomogram Based on Circular RNA-Associated Competing Endogenous RNA Network for Patients with Lung Adenocarcinoma.

Yang Li, Rongrong Sun, Rui Li, Yonggang Chen, He Du

Abstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yang LiDepartment of Central Laboratory, Affiliated Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou 221009, China.ORCID https://orcid.org/0000-0001-6769-2273
Rongrong SunDepartment of Medical Oncology, Affiliated Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou 221009, China.ORCID https://orcid.org/0000-0001-7250-9971
Rui LiDepartment of Central Laboratory, Affiliated Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou 221009, China.ORCID https://orcid.org/0000-0003-1044-1398
Yonggang ChenDepartment of Clinical Pharmacy, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou 221009, China.ORCID https://orcid.org/0000-0001-8189-2845
He DuDepartment of Medical Oncology, Affiliated Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China.ORCID https://orcid.org/0000-0003-3468-3869

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence is increasingly indicating that circular RNAs (circRNAs) are closely involved in tumorigenesis and cancer progression. However, the function and application of circRNAs in lung adenocarcinoma (LUAD) are still unknown. In this study, we constructed a circRNA-associated competitive endogenous RNA (ceRNA) network to investigate the regulatory mechanism of LUAD procession and further constructed a prognostic signature to predict overall survival for LUAD patients. Differentially expressed circRNAs (DEcircRNAs), differentially expressed miRNAs (DEmiRNAs), and differentially expressed mRNAs (DEmRNAs) were selected to construct the ceRNA network. Based on the TargetScan prediction tool and Pearson correlation coefficient, we constructed a circRNA-associated ceRNA network including 11 DEcircRNAs, 8 DEmiRNAs, and 49 DEmRNAs. GO and KEGG enrichment indicated that the ceRNA network might be involved in the regulation of GTPase activity and endothelial cell differentiation. After removing the discrete points, a PPI network containing 12 DEmRNAs was constructed. Univariate Cox regression analysis showed that three DEmRNAs were significantly associated with overall survival. Therefore, we constructed a three-gene prognostic signature for LUAD patients using the LASSO method in the TCGA-LUAD training cohort. By applying the signature, patients could be categorized into the high-risk or low-risk subgroups with significant survival differences (HR: 1.62, 95% CI: 1.12-2.35, log-rank

Indexed as

Adenocarcinoma of LungAdultAgedAged, 80 and overGene Regulatory NetworksHumansLung NeoplasmsMiddle AgedNomogramsPrognosisRNA, CircularRNA, Circular

Identifiers

PMID34497684
PMCPMC8421160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.